- Home
- MVBF vs ACIU Comparison
MVBF vs ACIU Comparison
Compare MVBF & ACIU Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MVBF
- ACIU
- Stock Information
- Founded
- MVBF 1997
- ACIU 2003
- Country
- MVBF United States
- ACIU Switzerland
- Employees
- MVBF N/A
- ACIU N/A
- Industry
- MVBF Major Banks
- ACIU Biotechnology: Pharmaceutical Preparations
- Sector
- MVBF Finance
- ACIU Health Care
- Exchange
- MVBF Nasdaq
- ACIU Nasdaq
- Market Cap
- MVBF 278.3M
- ACIU 189.1M
- IPO Year
- MVBF N/A
- ACIU 2016
- Fundamental
- Price
- MVBF $23.22
- ACIU $2.04
- Analyst Decision
- MVBF Buy
- ACIU Strong Buy
- Analyst Count
- MVBF 4
- ACIU 1
- Target Price
- MVBF $24.75
- ACIU $12.00
- AVG Volume (30 Days)
- MVBF 45.9K
- ACIU 123.5K
- Earning Date
- MVBF 07-28-2025
- ACIU 08-05-2025
- Dividend Yield
- MVBF 2.88%
- ACIU N/A
- EPS Growth
- MVBF N/A
- ACIU N/A
- EPS
- MVBF 1.46
- ACIU N/A
- Revenue
- MVBF $146,101,000.00
- ACIU $32,014,254.00
- Revenue This Year
- MVBF N/A
- ACIU N/A
- Revenue Next Year
- MVBF $14.22
- ACIU $533.21
- P/E Ratio
- MVBF $16.15
- ACIU N/A
- Revenue Growth
- MVBF N/A
- ACIU 91.20
- 52 Week Low
- MVBF $15.59
- ACIU $1.43
- 52 Week High
- MVBF $25.24
- ACIU $4.26
- Technical
- Relative Strength Index (RSI)
- MVBF 79.48
- ACIU 54.21
- Support Level
- MVBF $22.85
- ACIU $1.94
- Resistance Level
- MVBF $23.63
- ACIU $2.15
- Average True Range (ATR)
- MVBF 0.50
- ACIU 0.16
- MACD
- MVBF 0.13
- ACIU -0.00
- Stochastic Oscillator
- MVBF 95.93
- ACIU 72.22
About MVBF MVB Financial Corp.
MVB Financial Corp is a bank holding company. The company provides Personal banking, Business banking, and Fintech solutions. The group has identified three reportable segments: CoRe Banking, Mortgage Banking, and Financial Holding Company. The majority of ts revenue generated from the CoRe Banking segment, which includes the Fintech division, represents banking products and services offered to customers by the Bank, loans, and deposit accounts. Revenue from banking activities consists of interest earned on loans and investment securities and service charges on deposit accounts.
About ACIU AC Immune SA
AC Immune SA is a clinical-stage biopharmaceutical company that focuses on neurodegenerative diseases. The company uses its proprietary technology platforms to discover, design, and develop novel proprietary small molecules, antibodies, and vaccines for the prevention, diagnosis, and treatment of neurodegenerative diseases associated with protein misfolding. The Company has one segment. The Company currently focuses most of its resources on discovering and developing therapeutic and diagnostic products targeting misfolded proteins. The company's pipeline consists of ACI-24.060, Crenezumab, ACI-35.030, Semorinemab, ACI-7104.056, and others.